Open AccessA tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
Author(s) -
Vanita Noronha,
Vijay Patil,
Amit Joshi,
Atanu Bhattacharjee,
Davinder Paul,
Sachin Dhumal,
Shashikant Juvekar,
Supreeta Arya,
Kumar Prabhash
Publication year - 2017
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.202558
Subject(s) - medicine , cetuximab , head and neck cancer , regimen , interquartile range , mucositis , oncology , chemotherapy , hazard ratio , progression free survival , cancer , surgery , confidence interval , colorectal cancer
The combination of paclitaxel and cetuximab (PaCe) has led to an encouraging response rate in Phase 2 setting with limited toxicity. The aim of our study was to assess the efficacy of this regimen in our setting in platinum sensitive and nonsensitive patients.